NASDAQ:BVXV - BiondVax Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.65 -0.01 (-0.15 %)
(As of 05/27/2018 03:50 PM ET)
Previous Close$6.65
Today's Range$6.56 - $6.65
52-Week Range$4.60 - $10.75
Volume569 shs
Average Volume9,556 shs
Market Capitalization$43.46 million
P/E Ratio-3.36
Dividend YieldN/A
Beta1.19

About BiondVax (NASDAQ:BVXV)

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate includes M-001, a synthetic peptide-based protein, which is in Phase II clinical development stage targeting seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is based in Ness Ziona, Israel.

Receive BVXV News and Ratings via Email

Sign-up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BVXV
CUSIPN/A
Phone972-8930-2529

Debt

Debt-to-Equity RatioN/A
Current Ratio10.97
Quick Ratio10.97

Price-To-Earnings

Trailing P/E Ratio-3.36
Forward P/E Ratio-166.25
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.48 per share
Price / Book2.68

Profitability

EPS (Most Recent Fiscal Year)($1.98)
Net Income$-9,960,000.00
Net MarginsN/A
Return on Equity-78.39%
Return on Assets-55.34%

Miscellaneous

Employees14
Outstanding Shares6,530,000

BiondVax (NASDAQ:BVXV) Frequently Asked Questions

What is BiondVax's stock symbol?

BiondVax trades on the NASDAQ under the ticker symbol "BVXV."

How were BiondVax's earnings last quarter?

BiondVax (NASDAQ:BVXV) released its quarterly earnings results on Monday, April, 30th. The company reported ($0.59) earnings per share (EPS) for the quarter. View BiondVax's Earnings History.

When is BiondVax's next earnings date?

BiondVax is scheduled to release their next quarterly earnings announcement on Tuesday, May, 29th 2018. View Earnings Estimates for BiondVax.

Who are some of BiondVax's key competitors?

Who are BiondVax's key executives?

BiondVax's management team includes the folowing people:
  • Dr. Ron Babecoff DVM, Founder, Chief Exec. Officer, Pres & Director (Age 56)
  • Mr. Uri Ben-Or, Chief Financial Officer (Age 48)
  • Dr. Tamar Ben Yedidia Ph.D., Chief Scientific Officer (Age 54)
  • Dr. Shimon Hassin Ph.D., Chief Operating Officer
  • Mr. Joshua E. Phillipson, Bus. Devel. Mang.

When did BiondVax IPO?

(BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at a price of $7.32 per share. Aegis Capital Corp acted as the underwriter for the IPO.

Has BiondVax been receiving favorable news coverage?

Headlines about BVXV stock have been trending somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. BiondVax earned a news sentiment score of 0.08 on Accern's scale. They also gave news headlines about the company an impact score of 46.31 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of BiondVax?

Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BiondVax's stock price today?

One share of BVXV stock can currently be purchased for approximately $6.65.

How big of a company is BiondVax?

BiondVax has a market capitalization of $43.46 million. The company earns $-9,960,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. BiondVax employs 14 workers across the globe.

How can I contact BiondVax?

BiondVax's mailing address is 14 Einstein Street, Nes Ziona L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected]


MarketBeat Community Rating for BiondVax (BVXV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  61 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  117
MarketBeat's community ratings are surveys of what our community members think about BiondVax and other stocks. Vote "Outperform" if you believe BVXV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BVXV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BiondVax (NASDAQ:BVXV) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/27/2016 forward)

Earnings

BiondVax (NASDAQ:BVXV) Earnings History and Estimates Chart

Earnings by Quarter for BiondVax (NASDAQ:BVXV)

BiondVax (NASDAQ:BVXV) Earnings Estimates

2018 EPS Consensus Estimate: ($0.03)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.00$0.00$0.00
Q2 20181($0.01)($0.01)($0.01)
Q3 20181($0.01)($0.01)($0.01)
Q4 20181($0.01)($0.01)($0.01)

BiondVax (NASDAQ BVXV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/29/2018        
4/30/2018Q4 2017($0.59)ViewN/AView Earnings Details
11/28/2017Q3 2017$0.20ViewN/AView Earnings Details
8/31/2017Q2 2017($0.74)ViewN/AView Earnings Details
5/30/2017Q1 2017($0.80)ViewN/AView Earnings Details
4/28/2017Q4 2016($0.16)ViewN/AView Earnings Details
11/28/2016Q3 2016($0.01)($0.18)ViewN/AView Earnings Details
8/18/2016Q2 2016($0.01)($0.21)ViewN/AView Earnings Details
5/31/2016Q1 2016($0.01)($0.14)ViewN/AView Earnings Details
4/27/2016Q4 2015($0.25)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.01)ViewN/AView Earnings Details
8/24/2015Q2 2015($0.01)ViewN/AView Earnings Details
6/1/2015Q1 2015($0.01)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

BiondVax (NASDAQ:BVXV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

BiondVax (NASDAQ BVXV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.03%
Institutional Ownership Percentage: 7.29%
Insider Trading History for BiondVax (NASDAQ:BVXV)
Insider Trading History for BiondVax (NASDAQ:BVXV)

BiondVax (NASDAQ BVXV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

BiondVax (NASDAQ BVXV) News Headlines

Source:
DateHeadline
BiondVax (BVXV) Stock Rating Lowered by ValuEngineBiondVax (BVXV) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 11 at 11:13 AM
FY2018 EPS Estimates for BiondVax (BVXV) Cut by AnalystFY2018 EPS Estimates for BiondVax (BVXV) Cut by Analyst
www.americanbankingnews.com - May 9 at 9:36 AM
Equities Analysts Issue Forecasts for BiondVaxs Q1 2018 Earnings (BVXV)Equities Analysts Issue Forecasts for BiondVax's Q1 2018 Earnings (BVXV)
www.americanbankingnews.com - May 8 at 5:50 AM
BVXV: Set to Initiate Phase 3 Clinical Trial of Universal Influenza Vaccine Candidate in 2H18BVXV: Set to Initiate Phase 3 Clinical Trial of Universal Influenza Vaccine Candidate in 2H18
finance.yahoo.com - May 7 at 9:49 AM
BiondVax (BVXV) Upgraded to "Hold" by ValuEngineBiondVax (BVXV) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - May 3 at 11:47 PM
BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and UpdateBiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update
finance.yahoo.com - May 1 at 9:59 AM
An Ear To The Pharma: 9 Stocks To Watch This Week (RIGL, RARE, TROV, DVAX...)An Ear To The Pharma: 9 Stocks To Watch This Week (RIGL, RARE, TROV, DVAX...)
www.finanznachrichten.de - April 14 at 3:40 PM
BiondVax to Present at Universal Influenza Vaccines ConferenceBiondVax to Present at Universal Influenza Vaccines Conference
finance.yahoo.com - April 12 at 11:01 AM
BiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of Its Universal Flu Vaccine in the United StatesBiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of Its Universal Flu Vaccine in the United States
finance.yahoo.com - April 11 at 10:43 AM
BiondVax Pharmaceuticals (BVXV) Downgraded by ValuEngineBiondVax Pharmaceuticals (BVXV) Downgraded by ValuEngine
www.americanbankingnews.com - April 8 at 9:37 AM
BiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of Its Novel Universal Flu Vaccine CandidateBiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of Its Novel Universal Flu Vaccine Candidate
finance.yahoo.com - March 13 at 10:36 AM
BiondVax and European UNISEC Consortium to Host Universal Flu Vaccine ConferenceBiondVax and European UNISEC Consortium to Host Universal Flu Vaccine Conference
finance.yahoo.com - February 8 at 9:18 AM
BiondVax Universal Flu Vaccine Patent Granted in IndiaBiondVax Universal Flu Vaccine Patent Granted in India
finance.yahoo.com - January 2 at 9:49 AM
BiondVax Pharma (BVXV) Announces Plans for Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines AgencyBiondVax Pharma (BVXV) Announces Plans for Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency
www.streetinsider.com - December 27 at 10:52 PM
BiondVax Plans Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency (EMA)BiondVax Plans Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency (EMA)
finance.yahoo.com - December 27 at 5:51 PM
Equities Analysts Offer Predictions for BiondVax Pharmaceuticals Ltd.s FY2017 Earnings (BVXV)Equities Analysts Offer Predictions for BiondVax Pharmaceuticals Ltd.'s FY2017 Earnings (BVXV)
www.americanbankingnews.com - December 15 at 8:32 AM
BiondVax Pharmaceuticals Ltd. Expected to Post Q4 2017 Earnings of $0.00 Per Share (BVXV)BiondVax Pharmaceuticals Ltd. Expected to Post Q4 2017 Earnings of $0.00 Per Share (BVXV)
www.americanbankingnews.com - December 14 at 9:38 AM
BVXV: Planning Continues for M-001 Phase 3 Program …BVXV: Planning Continues for M-001 Phase 3 Program …
finance.yahoo.com - December 12 at 5:21 PM
BiondVax Pharmaceuticals (BVXV) Stock Rating Lowered by ValuEngineBiondVax Pharmaceuticals (BVXV) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - December 3 at 9:26 PM
BiondVax Provides Third Quarter 2017 Financial Results and UpdateBiondVax Provides Third Quarter 2017 Financial Results and Update
finance.yahoo.com - November 28 at 4:55 PM
BiondVax Pharma (BVXV) Reports Clinical Trial Agreement with NIH for U.S. Phase 2 Trial of Universal Flu VaccineBiondVax Pharma (BVXV) Reports Clinical Trial Agreement with NIH for U.S. Phase 2 Trial of Universal Flu Vaccine
www.streetinsider.com - November 21 at 5:01 PM
BiondVax Pharmaceuticals’ (BVXV) Quant Score Makes it BuyBiondVax Pharmaceuticals’ (BVXV) Quant Score Makes it Buy
investorplace.com - November 11 at 4:43 PM
BiondVax Pharmaceuticals’ (BVXV) Quant Score Makes it BuyBiondVax Pharmaceuticals’ (BVXV) Quant Score Makes it Buy
investorplace.com - November 10 at 4:43 PM
BVXV: Raises $10 Million to Help Support M-001 Pivotal P3 Program as Standalone Universal Influenza VaccineBVXV: Raises $10 Million to Help Support M-001 Pivotal P3 Program as Standalone Universal Influenza Vaccine
finance.yahoo.com - September 20 at 5:35 PM
BiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-allotment OptionBiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-allotment Option
finance.yahoo.com - September 18 at 5:08 PM
BiondVax Pharma (BVXV) Plans Public Offering of ADSsBiondVax Pharma (BVXV) Plans Public Offering of ADSs
www.streetinsider.com - September 14 at 5:32 PM
BiondVax Announces Pricing of Public Offering of American Depositary SharesBiondVax Announces Pricing of Public Offering of American Depositary Shares
finance.yahoo.com - September 13 at 11:04 PM
Should You Buy BiondVax Pharmaceuticals Ltd (BVXV)?Should You Buy BiondVax Pharmaceuticals Ltd (BVXV)?
finance.yahoo.com - September 13 at 6:03 PM
BiondVax Announces Public Offering of American Depositary SharesBiondVax Announces Public Offering of American Depositary Shares
finance.yahoo.com - September 13 at 6:03 PM
BiondVax Provides Second Quarter 2017 Financial Results and UpdateBiondVax Provides Second Quarter 2017 Financial Results and Update
finance.yahoo.com - August 31 at 4:45 PM
Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock ExchangeDual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange
finance.yahoo.com - August 31 at 4:45 PM
BiondVax Receives Additional Grant FundingBiondVax Receives Additional Grant Funding
finance.yahoo.com - August 14 at 5:16 PM
BVXV: Positive Results From Phase 2b Trial of M-001; Ready to Move Into Pivotal P3 Trial as Standalone Universal Influenza VaccineBVXV: Positive Results From Phase 2b Trial of M-001; Ready to Move Into Pivotal P3 Trial as Standalone Universal Influenza Vaccine
finance.yahoo.com - August 1 at 5:38 PM
BiondVax Reports Positive Phase 2b Clinical Trial Results for its Universal Flu VaccineBiondVax Reports Positive Phase 2b Clinical Trial Results for its Universal Flu Vaccine
finance.yahoo.com - July 20 at 6:31 PM
BiondVax Pharma (BVXV) Reports Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu VaccineBiondVax Pharma (BVXV) Reports Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine
www.streetinsider.com - July 19 at 6:46 AM
BiondVax Signs Lease Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu VaccineBiondVax Signs Lease Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine
finance.yahoo.com - July 18 at 6:21 PM
BVXV: Secures $22 Million Loan Agreement with European Investment Bank…BVXV: Secures $22 Million Loan Agreement with European Investment Bank…
finance.yahoo.com - July 6 at 6:05 PM
BiondVax Pharma (BVXV) Provides H1 General Corporate UpdateBiondVax Pharma (BVXV) Provides H1 General Corporate Update
www.streetinsider.com - June 28 at 9:50 PM
BiondVax Pharmaceuticals (BVXV) Leaps on Israeli NodBiondVax Pharmaceuticals (BVXV) Leaps on Israeli Nod
www.baystreet.ca - March 31 at 9:15 PM
Mid-Morning Market Update: Markets Edge Higher; Lululemon Issues Weak ForecastMid-Morning Market Update: Markets Edge Higher; Lululemon Issues Weak Forecast
www.nasdaq.com - March 30 at 9:31 PM
BiondVax Gets OK to Build Plant in Israel (BVXV)BiondVax Gets OK to Build Plant in Israel (BVXV)
www.investopedia.com - March 30 at 9:31 PM
BiondVax Gets Approval to Build Plant in IsraelBiondVax Gets Approval to Build Plant in Israel
www.investopedia.com - March 30 at 4:29 PM
BiondVax Pharma (BVXV) Publishes Regulatory Approval Strategy for Novel Universal Flu VaccinesBiondVax Pharma (BVXV) Publishes Regulatory Approval Strategy for Novel Universal Flu Vaccines
www.streetinsider.com - March 13 at 12:43 PM
BiondVax Gets $2.8 Mln Investment From Check Point Chairmans Angels High TechBiondVax Gets $2.8 Mln Investment From Check Point Chairman's Angels High Tech
www.nasdaq.com - January 2 at 4:27 PM
BiondVax Announces Third Quarter 2016 Financial Results and UpdateBiondVax Announces Third Quarter 2016 Financial Results and Update
us.rd.yahoo.com - November 30 at 6:31 AM
BiondVax Phase 2b Trial Preliminary Safety Results: The Universal Flu Vaccine Candidate is Safe and Well ToleratedBiondVax Phase 2b Trial Preliminary Safety Results: The Universal Flu Vaccine Candidate is Safe and Well Tolerated
us.rd.yahoo.com - November 30 at 6:31 AM
7:31 am BiondVax Pharmaceuticals announces positive preliminary safety results from its European Phase 2b clinical trial of M-001, its universal flu vaccine candidate7:31 am BiondVax Pharmaceuticals announces positive preliminary safety results from its European Phase 2b clinical trial of M-001, its universal flu vaccine candidate
us.rd.yahoo.com - November 30 at 6:31 AM
Biondvax Pharma chief investigated for improper use of internal information, released subject to restrictionsBiondvax Pharma chief investigated for improper use of internal information, released subject to restrictions
seekingalpha.com - March 30 at 2:46 PM

SEC Filings

BiondVax (NASDAQ:BVXV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BiondVax (NASDAQ:BVXV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BiondVax (NASDAQ BVXV) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.